Published in Medical Letter on the CDC and FDA, December 10th, 2006
Net loss applicable to common shareholders totaled $1.5 million, or $0.03 per share, for the third quarter of 2006, compared to net loss applicable to common shareholders of $2.2 million, or $0.04 per share, for the second quarter of 2006.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.